BR0211379A - Sìntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase - Google Patents

Sìntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase

Info

Publication number
BR0211379A
BR0211379A BR0211379-1A BRPI0211379A BR0211379A BR 0211379 A BR0211379 A BR 0211379A BR PI0211379 A BRPI0211379 A BR PI0211379A BR 0211379 A BR0211379 A BR 0211379A
Authority
BR
Brazil
Prior art keywords
synthesis
glycosyltransferase
udp
glucose
inhibitors
Prior art date
Application number
BR0211379-1A
Other languages
English (en)
Inventor
Bradford H Hirth
Craig Siegel
James A Shayman
Carol Anne Nelson
David J Harris
Diane Copeland
Original Assignee
Genzyme Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0211379(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Michigan filed Critical Genzyme Corp
Priority to BR122015016313A priority Critical patent/BR122015016313B8/pt
Priority to BR122015016314A priority patent/BR122015016314B8/pt
Publication of BR0211379A publication Critical patent/BR0211379A/pt
Publication of BRPI0211379B1 publication Critical patent/BRPI0211379B1/pt
Publication of BRPI0211379B8 publication Critical patent/BRPI0211379B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"SìNTESE DE INIBIDORES DE UDP-GLICOSE: N-ACIL-ESFINGOSINA GLICOSILTRANSFERASE". Divulgam-se novos inibidores como ceramida de síntese enantiomérica de UDP-glicose: N-acil-esfingosina glicosiltransferase. Divulgam-se também novos intermediários formados durante a síntese.
BRPI0211379-1 2001-07-16 2002-07-16 síntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase BRPI0211379B8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122015016313A BR122015016313B8 (pt) 2001-07-16 2002-07-16 composto semelhante à ceramida e método de preparar um composto
BR122015016314A BR122015016314B8 (pt) 2001-07-16 2002-07-16 método para preparar um composto acíclico, método para preparar um composto amina, método para preparar um composto do tipo esfingosina e método para preparar um composto do tipo ceramida

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
US60/305,814 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Publications (3)

Publication Number Publication Date
BR0211379A true BR0211379A (pt) 2004-08-17
BRPI0211379B1 BRPI0211379B1 (pt) 2018-02-14
BRPI0211379B8 BRPI0211379B8 (pt) 2021-05-25

Family

ID=23182463

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0211379-1 BRPI0211379B8 (pt) 2001-07-16 2002-07-16 síntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase
BR122015016313A BR122015016313B8 (pt) 2001-07-16 2002-07-16 composto semelhante à ceramida e método de preparar um composto
BR122015016314A BR122015016314B8 (pt) 2001-07-16 2002-07-16 método para preparar um composto acíclico, método para preparar um composto amina, método para preparar um composto do tipo esfingosina e método para preparar um composto do tipo ceramida

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122015016313A BR122015016313B8 (pt) 2001-07-16 2002-07-16 composto semelhante à ceramida e método de preparar um composto
BR122015016314A BR122015016314B8 (pt) 2001-07-16 2002-07-16 método para preparar um composto acíclico, método para preparar um composto amina, método para preparar um composto do tipo esfingosina e método para preparar um composto do tipo ceramida

Country Status (16)

Country Link
US (11) US6855830B2 (pt)
EP (3) EP2067775B1 (pt)
JP (6) JP5038582B2 (pt)
AT (2) ATE555102T1 (pt)
BE (1) BE2015C029I2 (pt)
BR (3) BRPI0211379B8 (pt)
CA (1) CA2453978C (pt)
CY (1) CY2015028I2 (pt)
DK (3) DK2067775T3 (pt)
ES (3) ES2399323T3 (pt)
FR (1) FR15C0036I2 (pt)
HK (2) HK1132267A1 (pt)
IL (3) IL159905A0 (pt)
LU (1) LU92717I2 (pt)
PT (3) PT1409467E (pt)
WO (1) WO2003008399A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ES2399323T3 (es) * 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
US6835831B2 (en) * 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
US8003617B2 (en) * 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
ES2436612T3 (es) 2005-01-26 2014-01-03 Allergan, Inc. 3-heteroaril-3-hidroxi-2-amino-propilaminas y compuestos relacionados que tienen actividad analgésica y/o inmunoestimulante
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
IL243117B2 (en) 2007-01-18 2023-03-01 Genzyme Corp Oligosaccharides containing an amino group and their conjugates
WO2008109610A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008109285A1 (en) 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
EP2550965B1 (en) 2007-10-05 2019-01-16 Genzyme Corporation Ceramide derivatives for treating polycystic kidney disease
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255B1 (en) 2008-10-03 2016-03-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
CA2781676C (en) * 2009-11-27 2020-05-05 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP3236686A1 (en) 2010-04-16 2017-10-25 Kyocera Corporation Radio communication system, high-power base station, low-power base station, and communication control method
EP2699676A1 (en) 2011-04-22 2014-02-26 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
AU2014237569B2 (en) * 2013-03-15 2019-03-14 Concert Pharmaceuticals Inc. Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
AU2014321397C1 (en) 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
HUE040220T2 (hu) 2013-10-29 2019-02-28 Biomarin Pharm Inc N-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3-karboxamid származékok mint glükozilceramid-szintáz inhibitorok
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
ES2716420T3 (es) 2015-04-14 2019-06-12 Sandoz Ag Clorhidrato de eliglustat cristalino
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
WO2017178499A1 (en) 2016-04-11 2017-10-19 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
MX2020006272A (es) 2017-12-15 2020-09-14 Genzyme Corp Metodos para tratar la enfermedad de gaucher.
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
WO2020194138A1 (en) * 2019-03-22 2020-10-01 Piramal Enterprises Limited An improved process for the preparation of eliglustat and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
US20230212123A1 (en) 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
AU676361B2 (en) * 1993-08-13 1997-03-06 Seikagaku Corporation Remedy for nervous diseases
PT742789E (pt) * 1994-02-02 2000-12-29 Liposome Co Inc Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
DE69524592T2 (de) * 1994-06-10 2002-07-18 Seikagaku Kogyo Co Ltd 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6511979B1 (en) * 1998-07-27 2003-01-28 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2004531478A (ja) * 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
HUE026057T2 (en) * 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis

Also Published As

Publication number Publication date
EP1409467A1 (en) 2004-04-21
US7196205B2 (en) 2007-03-27
CA2453978A1 (en) 2003-01-30
CY2015028I1 (el) 2016-07-27
US7763738B2 (en) 2010-07-27
BR122015016313B1 (pt) 2019-04-16
JP5227348B2 (ja) 2013-07-03
US20050009872A1 (en) 2005-01-13
PT2067775E (pt) 2012-07-16
US20150148534A1 (en) 2015-05-28
ES2395463T4 (es) 2013-02-12
JP2017075151A (ja) 2017-04-20
US6855830B2 (en) 2005-02-15
US20120296088A1 (en) 2012-11-22
DK2067775T3 (da) 2012-07-16
EP2266968A3 (en) 2011-05-18
IL159905A0 (en) 2004-06-20
US7615573B2 (en) 2009-11-10
ATE554082T1 (de) 2012-05-15
US20070203223A1 (en) 2007-08-30
IL193244A0 (en) 2009-02-11
LU92717I2 (fr) 2015-11-24
EP2067775B1 (en) 2012-04-25
US9546161B2 (en) 2017-01-17
BR122015016314B8 (pt) 2021-05-25
US20030050299A1 (en) 2003-03-13
BR122015016313B8 (pt) 2021-05-25
FR15C0036I2 (fr) 2016-05-27
PT2266968E (pt) 2013-02-25
CY2015028I2 (el) 2016-07-27
EP2266968A2 (en) 2010-12-29
US20080058514A1 (en) 2008-03-06
US20110003987A1 (en) 2011-01-06
US20050222244A1 (en) 2005-10-06
ATE555102T1 (de) 2012-05-15
US7265228B2 (en) 2007-09-04
ES2399323T3 (es) 2013-03-27
ES2395463T3 (es) 2013-02-15
HK1132267A1 (en) 2010-02-19
US20210171507A1 (en) 2021-06-10
JP2005255686A (ja) 2005-09-22
HK1153733A1 (pt) 2012-04-05
US8779163B2 (en) 2014-07-15
JP2015180656A (ja) 2015-10-15
BRPI0211379B8 (pt) 2021-05-25
JP2005502635A (ja) 2005-01-27
CA2453978C (en) 2011-10-11
US20170334888A1 (en) 2017-11-23
BE2015C029I2 (pt) 2021-07-19
EP2266968B1 (en) 2013-01-09
IL159905A (en) 2009-05-04
JP6182254B2 (ja) 2017-08-16
DK1409467T3 (da) 2012-07-16
JP5038582B2 (ja) 2012-10-03
EP2067775A1 (en) 2009-06-10
US20190322649A1 (en) 2019-10-24
JP4708073B2 (ja) 2011-06-22
JP2010095546A (ja) 2010-04-30
WO2003008399A1 (en) 2003-01-30
BRPI0211379B1 (pt) 2018-02-14
DK2266968T3 (da) 2013-04-08
PT1409467E (pt) 2012-10-24
BR122015016314B1 (pt) 2019-04-16
JP2013136618A (ja) 2013-07-11
ES2395122T3 (es) 2013-02-08
FR15C0036I1 (pt) 2015-06-26
EP1409467B1 (en) 2012-04-18
US8138353B2 (en) 2012-03-20

Similar Documents

Publication Publication Date Title
BR0211379A (pt) Sìntese de inibidores de udp-glicose: n-acil-esfingosina glicosiltransferase
SE0000540D0 (sv) New compounds
EP1613728A4 (en) MODULATION OF EXPRESSION OF DIACYLGLYCEROL ACYLTRANSFERASE 1
ITMI20021876A1 (it) Procedimento migliorato per realizzare un rotore di un
BG105515A (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
UY26721A1 (es) Nuevos derivados de la fenilglicina
NO20024808D0 (no) Fremgangsmåte ved syntesen av perindopril og farmasöytisk akseptable salter derav
RS81904A (en) Phosphate prodrugs of fluorooxindoles
FR2833089B1 (fr) Regulateur de pression du type a volet d'etranglement
AU2003248647A8 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
FR2850042B1 (fr) Generateur d'efforts dynamiques a balourd
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
HUP9802586A2 (hu) A (-)-[2-(2-tienil)-etilamino]-(2-halogénfenil)-acetamidok racemizálási eljárása
ITMI20010077A0 (it) Procedimento per la produzione dell'imipenem
ITMI20000026A0 (it) Procedimento per la produzione di gas di sintesi
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
CY1113586T1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
AU2001258344A1 (en) Synthesis of midodrine hci from a novel intermediate 1-(2',5'-dimethoxyphenyl)-2-azidoethanone
HUP0300100A2 (en) Peptide betha-turn mimetic compounds and processes for making them
IT1316990B1 (it) Metodo per aumentare l'espressione genica per geni trasfettati.
DE60224381D1 (de) Neuer sphingolipid-synthese-hemmer
FR2849768B1 (fr) Distributeur d'instruments dentaires
AU2003222958A1 (en) Asymmetric synthesis of glycidic amides

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US) , THE REGENTS OF THE UNIV

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 295/12, C07C 231/18, C07C 215/30, C07C 237/20, C07D 498/04, A61P 35/00

Ipc: C07D 295/12 (2011.01), C07C 231/18 (2011.01), C07C

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US) , THE REGENTS OF THE UNIV

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: "INPI NO 52402.000121/2022-46 ORIGEM: 4A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1088996-39.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM AUTOR: GENZYME CORPORATION E THE REGENTS OF THE UNIVERSITYOF MICHIGAN REU(S): INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL"

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.001404/2023-96 TRIBUNAL REGIONAL FEDERAL DA PRIMEIRA REGIAO AUTOR: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AUTOR: GENZYME CORPORATION REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO: ANTE O EXPOSTO, PRESENTES OS REQUISITOS AUTORIZADORES, DEFIRO O PEDIDO DE ANTECIPACAO DA TUTELA RECURSAL, A FIM DE SUSPENDER OS EFEITOS DO DESPACHO 16.3 DO INPI, IMPEDINDO-SE, ASSIM, A DECLARACAO DE EXTINCAO DO PRAZO DA PATENTE PI 0211379-1 PELO INPI.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: "INPI NO 52402.001404/2023-96 ORIGEM: TRIBUNAL REGIONAL FEDERAL DA 1A REGIAO PROCESSO NO: 1001008-24.2023.4.01.0000 SUB JUDICE COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: GENZYME CORPORATION E THEREGENTS OF THE UNIVERSITY OF MICHIGAN, REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI"